NFATC2IP and cardiac hypertrophy: The study points to a new pathogenic mechanism for microRNA‐associated cardiac hypertrophy, suggesting the miR‐31‐5p/Nfatc2ip/β‐Mhc pathway as a potential target for cardiac hypertrophy.